Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids on Plasma Reproductive Hormones, Fertility, Withdrawal Symptoms and Myocardial Function - The LUCAS Trial
Conditions
Interventions
Letrozole 2.5mg, hCG
Placebo
Locations
1
Denmark
Rigshospitalet
Copenhagen, Denmark
Start Date
November 24, 2021
Primary Completion Date
August 15, 2023
Completion Date
August 15, 2023
Last Updated
February 15, 2024
NCT07546435
NCT06019182
NCT06689085
NCT06583408
NCT06841328
NCT03851627
Lead Sponsor
Rigshospitalet, Denmark
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions